Prime Medicine PRME Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $77.8M-26.6% | $76.72M-61.0% | $85.09M-35.6% | $67.5M-2.3% | $105.94M-1.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$120K-100% | $120K— | $17K— | ||
| $137.89M-15.8% | $181.29M-14.4% | $231.41M-6.0% | $121.29M-29.0% | $163.77M-24.8% | ||
| $18.82M-24.6% | $20.57M-15.7% | $22.05M-5.3% | $23.83M+0.1% | $24.96M+4.3% | ||
| $294.73M-10.2% | $342.73M+15.2% | $385.01M+15.7% | $279.01M+7.4% | $328.16M+5.4% | ||
| $36.94M+17.5% | $34.64M+10.0% | $37.11M-6.5% | $33.18M-31.4% | $31.44M-36.1% | ||
| $7.32M— | $7.82M— | $6.95M— | $8.32M— | —— | ||
| $36.29M+5.8% | $37.45M-1.4% | $35.02M-7.5% | $34.11M+64.4% | $34.29M+40.3% | ||
| $218.03M-1.5% | $221.87M+53.7% | $223.19M+55.8% | $218.15M+246% | $221.24M+227% | ||
| 775M0.0% | 775M+38,749,900% | 775M0.0% | 775M0.0% | 775M0.0% | ||
| -$937.48M-26.8% | -$888.35M-29.3% | -$842.28M-30.6% | -$791.69M-33.6% | -$739.1M-37.6% | ||
| $76.7M-28.3% | $120.87M-21.1% | $161.82M-14.6% | $60.86M-69.0% | $106.92M-56.1% | ||
| $294.73M-10.2% | $342.73M+15.2% | $385.01M+15.7% | $279.01M+7.4% | $328.16M+5.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Prime Medicine's total assets?
- Prime Medicine (PRME) holds $294.7M in total assets, down 10.2% year over year.
- How much debt does Prime Medicine have?
- Prime Medicine carries $114.5M in total debt against $76.7M of shareholders' equity, a debt-to-equity ratio of 1.49.
- How much cash does Prime Medicine have?
- Prime Medicine holds $77.8M in cash and equivalents.
- Can Prime Medicine cover its short-term obligations?
- Its current ratio is 3.80 — current assets exceed current liabilities.
- Where does Prime Medicine's balance sheet data come from?
- Every line is extracted from Prime Medicine's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
